* Equillium Inc reported a quarterly adjusted loss of 7 cents per share for the quarter ended in December, lower than the same quarter last year, when the company reported EPS of 8 cents. The mean expectation of four analysts for the quarter was for a loss of 17 cents per share. Wall Street expected results to range from -29 cents to -9 cents per share.
* Revenue fell 41.6% to $9.21 million from a year ago; analysts expected $6.43 million.
* Equillium Inc's reported EPS for the quarter was a loss of 7 cents.
* The company reported a quarterly loss of $2.33 million.
* Equillium Inc shares had risen by 290.0% this quarter.
FORECAST CHANGES
* The mean earnings estimate of analysts was unchanged in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the pharmaceuticals peer group is "buy."
Wall Street's median 12-month price target for Equillium Inc is $7.00 This summary was machine generated from LSEG data March 25 at 09:00 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Dec. 31 2023 -0.17 -0.07 Beat
Sep. 30 2023 -0.17 -0.11 Beat
Jun. 30 2023 -0.17 -0.10 Beat
Mar. 31 2023 -0.27 -0.11 Beat
Comments